Algorae Pharmaceuticals (ASX:1AI) disclosed at its 2026 Annual General Meeting on 5 November 2026 that it holds seven product registrations under review with the Therapeutic Goods Administration, has secured a supplier position with NSW public hospitals, and closed the financial year with cash and term deposits of $3.94 million, up from $2.32 million a year earlier.

Key Points

  • Seven product registration dossiers currently under TGA review, with the Umedica Laboratories dossier lodged last month
  • AlgoraeRx appointed supplier to NSW public hospitals under a standing offer arrangement with NSW Health for an initial three-year term with two one-year extension options
  • $4.0 million capital raise completed in April, principally from existing long-term shareholders; year-end cash and term deposits of $3.94 million
  • AlgoraeOS Version 2, trained on more than 5.5 million inhibition records, outperformed state-of-the-art models in published benchmarks including two from Google DeepMind
  • $3.0 million working capital facility secured with ScotPac in January; facility remained undrawn at 30 September with total available funding of $6.15 million

AlgoraeRx Commercial Partnerships and TGA Registration Progress

According to the Chairman's address, AlgoraeRx has executed supply and licensing agreements with Sakar Healthcare, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Lifesciences, Torrent Pharmaceuticals, and most recently Umedica Laboratories, the latter covering one confirmed product and a non-binding memorandum of understanding for eight further molecules. The filing states these agreements provide a portfolio of more than twenty products across oncology, cardiovascular, metabolic and specialty medicines. The TGA accepted the company's first product registration dossier for evaluation in April, and seven dossiers are currently under review.

NSW Health Hospital Supply Appointment and First Customer Receipts

Following a competitive tender, AlgoraeRx was appointed a supplier to NSW public hospitals under a standing offer arrangement with NSW Health, the filing states. The arrangement carries an initial three-year term with two one-year extension options. The company disclosed that onboarding and rollout are under way and that first supply under purchase orders is expected in the current quarter. The filing also states that the September quarter brought the company's first customer receipts. To fund inventory, Algorae secured a $3.0 million working capital facility with ScotPac in January, which remained undrawn at 30 September.

AlgoraeOS Platform Validation and Peter Mac Research Programs

The Chairman's address stated that AlgoraeOS Version 2 was launched in November 2025, developed with the UNSW AI Institute and supported by CSIRO Data61. Independent testing at Peter Mac showed Version 2 identified a roughly two-and-a-half-fold higher proportion of confirmed synergistic combinations than Version 1. A multi-anchor program generated more than nine million predictions, from which 40 high-priority candidates have been curated and are being screened in a third Peter Mac program, co-funded by a competitive Phenomics Australia grant. Results from that program are expected within six months, according to the filing.